Corbevax covid vaccine approved for emergency use on children aged 12 to 18

News Network
February 21, 2022

Bengaluru, Feb 21: Indian vaccine maker Biological E Ltd said on Monday its Covid-19 vaccine received an emergency use approval in the country for use in children aged 12 to 18.

The company's shot, called Corbevax, is the third vaccine approved for use in children aged 12 and above in India, joining Zydus Cadila's DNA shot ZyCoV-D and homegrown player Bharat Biotech's Covaxin.

India has so far only started vaccinating children aged 15 and above. According to government figures, more than 76 million children between 15 and 17 years have been inoculated mainly using Covaxin.

The emergency use approval for restricted use in the 12-18 age group for Corbevax is based on interim results of an ongoing mid to late stage clinical study, Biological E said in an emailed statement.

Corbevax in late last December was given emergency use approval for use in adults, but it has yet to be included in the national immunisation programme.

Nearly 1.76 billion vaccine doses have been used in India's vaccination programme so far, of which about 84 per cent has been a domestic version of AstraZeneca's Covid-19 shot produced by the Serum Institute of India.

India's third wave of Covid-19 cases driven by the Omicron coronavirus variant has largely receded, with the country reporting 16,051 infections on Monday compared to more than 300,000 in late January. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 8,2025

Mangaluru: Air India Express (AIE) has postponed its much-anticipated direct flight service between Mangaluru International Airport (MIA) and Singapore, citing low bookings. Passengers who had booked tickets for the inaugural flight scheduled for January 21 and subsequent dates have been notified of the cancellation through email.

In its email, AIE assured passengers of alternative travel arrangements, including connecting flight options between MIA and Singapore. However, the decision to delay the direct service has left travelers and travel agents disappointed.

An AIE official attributed the postponement to operational challenges but clarified that the airline has not abandoned plans for the route. “We are committed to starting the service, but there is no immediate confirmation on the new launch date,” the official stated. He further explained that sustaining a route requires consistent demand, and seasonal travel alone is insufficient to justify operations.

Another AIE representative admitted that the number of bookings for the inaugural flight was below expectations but declined to disclose specific figures.

Rajesh H Acharya, director of HQ Connections Pte Ltd in Singapore and coordinator of the Singapore Tuluver community, expressed his disappointment. Acharya, who has been advocating for a direct flight between Mangaluru and Singapore since 2017, said, “After years of effort, we finally convinced the airline to start this service, but it has now been deferred.”

Taking to X (formerly Twitter), Acharya posted: "Did not expect such behavior from @AirIndiaX, now owned by @TataCompanies & @SIAirlines. If there are issues, travelers deserve to be informed well in advance. This decision needs investigation at the highest level."

The delay has raised questions among the travel community, with many hoping the airline will address these concerns and provide a clear timeline for the launch of the Mangaluru-Singapore direct flight.

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 9,2025

Mangaluru: In a significant development, Mescom has proposed a phased electricity tariff hike starting with Rs 0.70 per unit for the fiscal year 2025-26. The proposal has been submitted to the Karnataka Electricity Regulatory Commission (KERC) for approval, signaling a potential increase in electricity costs for consumers.

Mescom emphasized that the current tariff structure is insufficient to meet operational expenses and manage revenue effectively. To address this, the company has invited public objections to the proposed hike.

Currently, the electricity supply cost is Rs 9.23 per unit, while the consumer tariff stands at Rs 8.53 per unit, leading to a shortfall of Rs 0.70 per unit. For the financial year 2023-24, Mescom reported revenue of Rs 5,924.73 crore against an expenditure of Rs 6,310.39 crore, resulting in a deficit of Rs 367.66 crore. For the 2025-26 fiscal year, projected revenue is Rs 5,850.81 crore, with an actual requirement of Rs 5,961.63 crore, creating a deficit of Rs 110.82 crore.

In a first, Mescom has submitted a multi-year tariff revision proposal to KERC. The plan outlines a hike of Rs 0.70 per unit for 2025-26, followed by Rs 0.37 per unit for 2026-27 and Rs 0.54 per unit for 2027-28.

"An increase in electricity tariff is inevitable," stated Jayakumar R, Managing Director of Mescom. "Mescom has submitted a proposal in this regard to KERC."

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.
News Network
January 6,2025

Two cases of Human Metapneumovirus (HMPV) were reported in Bengaluru on January 6 - a 3-month-old baby who has been discharged and an 8-month-old who is recovering at a hospital in the Karnataka capital. This marks the first reported cases of HMPV in India.

The infected infants and their families have no recent travel history, ruling out exposure from other regions or countries, the health department said.

HMPV is a respiratory virus that often causes mild symptoms resembling a cold but can lead to other complications, particularly in infants, the elderly, and those with weakened immune systems. The virus can occasionally trigger pneumonia or exacerbate chronic respiratory conditions. Cases typically rise during the winter and early spring.

The Centre announced on Sunday that it is monitoring HMPV and other respiratory viruses, especially following recent reports of increased respiratory illnesses in China. A Joint Monitoring Group (JMG) convened on January 4 to evaluate the situation, with representatives from the World Health Organisation (WHO), National Centre for Disease Control (NCDC), Indian Council of Medical Research (ICMR), and other health organisations participating.

Respiratory illnesses in China align with seasonal variations caused by viruses such as influenza, RSV, and HMPV. Current surveillance data from India does not indicate any unusual surge in respiratory infections, according to the Ministry of Health and Family Welfare.

As a precaution, the Centre has increased laboratory capacity for HMPV testing. The ICMR will monitor HMPV trends throughout the year, alongside other respiratory illnesses such as influenza-like illness (ILI) and severe acute respiratory infections (SARI). A robust network of surveillance systems, including those operated by ICMR and the Integrated Disease Surveillance Programme (IDSP), continues to track respiratory infections across the country.

Hospitals have been advised to strengthen isolation protocols for suspected cases, ensure the availability of essential medicines, and promptly report ILI and SARI cases through the Integrated Health Information Platform (IHIP).

Precautions to Take:

To reduce the risk of HMPV infection, individuals are advised to:

  • Wash hands frequently with soap and water for at least 20 seconds.
  • Avoid close contact with people who have respiratory symptoms.
  • Wear masks in crowded or high-risk areas, especially during seasonal outbreaks.
  • Maintain good indoor ventilation by keeping windows open when possible.
  • Disinfect commonly touched surfaces regularly, such as doorknobs, toys, and tables.
  • Monitor infants, the elderly, and people with chronic illnesses for symptoms like persistent cough or breathing difficulties.
  • Seek prompt medical attention if respiratory symptoms worsen or persist. 

Comments

Add new comment

  • Coastaldigest.com reserves the right to delete or block any comments.
  • Coastaldigset.com is not responsible for its readers’ comments.
  • Comments that are abusive, incendiary or irrelevant are strictly prohibited.
  • Please use a genuine email ID and provide your name to avoid reject.